RESULTS: The mean age was 45 years and mean baseline body mass index was 34 kg/m(2); 76% were women.
Mean baseline body weight was 87.1 kg.
Mean baseline body weight was 109.5 ± 2.7 and 107.6 ± 2.6 kg with exenatide and placebo, respectively.
Mean baseline body weight and BMI was 104 kg and 36 kg/m, respectively.
Individuals in trials with a mean baseline body mass index ≥40 lost more body weight than individuals in trials with a mean baseline body mass index <40 (difference of the mean difference −13 kg, P<0.001) (appendix fig 2).
Mean baseline body weight, waist circumference, and BMI was 100 kg, 109 cm, and 36 kg/m, respectively.
In the present study, typical of an Asian population with relatively low mean baseline BMI and body weight (25 kg/m and 66 kg, respectively), observed weight changes were generally small.
In addition to the outcomes specified above, we extracted the number of participants allocated to intervention and control groups, distribution of sex, mean age at baseline, body mass index at baseline, baseline pain (transformed into a visual analogue pain scale from 0 to 100 mm), and interventions performed in the intervention and control groups.
Meanwhile, mean adjusted changes from baseline body weight ranged from −1.0 to −4.54 kg with dapagliflozin, compared with +1.8 to −2.12 kg for placebo (Table 2).
Corresponding mean adjusted changes from baseline body weight were −0.72, −1.56 and −2.26 kg, respectively, for placebo, dapagliflozin 5 mg (P < 0.001 vs. placebo), and 10 mg (P < 0.0001 vs. placebo), respectively.
At 24 weeks, the mean adjusted changes from baseline body weight were +1.64, +0.09 and −0.14 kg, respectively, for placebo, dapagliflozin 5 mg, and dapagliflozin 10 mg (both P < 0.001 vs. placebo).
